Moxisylyte hydrochloride

Cat. No.: HY-B1435
CAS No.: 964-52-3
Molecular Formula: C₁₆H₂₆ClNO₃
Molecular Weight: 315.84
Target: Adrenergic Receptor
Pathway: GPCR/G Protein; Neuronal Signaling
Storage: Powder
-20°C 3 years
4°C 2 years
In solvent
-80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro
H₂O : ≥ 50 mg/mL (158.31 mM)
DMSO : 20 mg/mL (63.32 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent</th>
<th>Mass (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>3.1662 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.6332 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.3166 mL</td>
</tr>
</tbody>
</table>

Preparing Stock Solutions

In Vivo
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2 mg/mL (6.33 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2 mg/mL (6.33 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2 mg/mL (6.33 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
Moxisylyte (hydrochloride) is (alpha 1-blocker) antagonist, it can vasodilates cerebral vessels without reducing blood pressure. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. [1][2]
REFERENCES
